- RBC Capital has raised its price target for Argenx to $1,025, maintaining an Outperform rating.
- The company reported robust Q2 product net sales of $1.5 billion, marking a 60% year-over-year increase, driven by strong Vyvgart performance.
- Argenx demonstrates consistent expansion with its 18th consecutive quarter of growth, aligning with its “Vision 2030” strategic plan.
Argenx (NASDAQ: ARGX) is a Belgian-Dutch immunology company that develops therapies for severe autoimmune diseases. The company’s primary product is Vyvgart, a treatment that has become a significant source of its revenue. Argenx focuses on conditions where the body’s immune system mistakenly attacks its own cells and tissues.
Following recent performance, RBC Capital raises its price target for Argenx to $1,025 from $945. The firm also maintains an Outperform rating on the stock. An Outperform rating means the analyst expects the stock’s returns to be better than the average return of other stocks in its sector.
This positive outlook is supported by strong sales growth. As highlighted by Reuters, global sales of Vyvgart increased significantly. Chief Financial Officer Karl Gubitz reported that second-quarter product net sales reached $1.5 billion. This represents a 60% increase from the same period last year and a 17% rise from the first quarter.
The company’s performance shows consistent expansion, marking its 18th consecutive quarter of growth. According to a Q2 2026 earnings call transcript from Seeking Alpha, CEO Karen Massey noted the strong quarter reflects the value Vyvgart provides. This progress aligns with the company’s “Vision 2030” plan for future growth.
The stock is currently trading at $924.60, a gain of 8.56% for the day. Argenx has a market capitalization of about $57.50 billion, which is the total market value of the company’s outstanding shares. Over the past 52 weeks, the stock’s price has ranged from a low of $577.04 to a high of $953.58.
